| Home \ Conferences and Programmes \ Health and Welfare \ HTA \ HTApublications |
|
HTA PublicationsStockholm Network - Launched in March 2007, the Stockholm Network's Health Technology Assessment (HTA) series focuses both on the political motivations and economic rationale of HTA. Among other things, it aims to highlight the gap between the theory and practice of HTA, as well as the extent to which the HTA process is exercised by different national bodies. An Introduction to Health Technology Assessment by Dr Meir P Pugatch and Francesca Ficai, Stockholm Network
-
This paper explains what HTA is, why it has evolved, and highlights the gap that exists between HTA theory and its actual application. The authors define HTA as the generation of evidence-based tools for prioritising health care treatments in terms of their utility, efficiency and cost-effectiveness. Among the driving forces behind HTA is the rapid growth of medical technology and the increasing volume of new knowledge. HTA emerges as a logical policy tool – assuming a state-centric approach and a publicly funded health systems.
A Healthy Market? Health Technology Assessment in Context by Helen Davison and Dr Meir P Pugatch, Stockholm Network
This paper focuses on the historical, political and economic developments that have led to the creation of institutional HTA processes and bodies.
Health Technology Assessment in the by Kristian Niemietz and Dr Meir P Pugatch, Stockholm Network
This paper analyses the performance of the National Institute for Health and Clinical Excellence (NICE) and the Institute for Quality and Efficiency in Health Care (IQWiG) in terms of relevance, strategy, responsibility, transparency and stakeholder involvement, all in the wider context of the strengths and weaknesses of HTA as a form of healthcare rationing tool.
-
by the Stockholm Network
-
This paper explores the concept of spending limits within HTA bodies and so-called thresholds. The paper finds that even in countries where the use of HTA is advanced, stakeholders of the respective health systems have no way of knowing what rationale HTA decisions are really based on. HTA bodies in the world typically avoid defining clearly (and even intentionally avoid making public) what threshold they are using to determine the cost-effectiveness of a given treatment. Yet this does not necessarily have to be the case.
-
by the Stockholm Network
-
In this paper, the Stockholm Network explores the issue of governance of HTA systems. It finds that, while there seems to be a convergence among different countries towards the HTA appraisal and review process, there are still considerable differences in the manner in which national HTA system operate as a whole. Such differences, it is argued, ultimately lead to different outcomes and outputs of national HTA systems, not least in the context of patients` ability to access new and innovative healthcare technologies.
-
Other-
By Karen Facey and the Centre for the New Europe
-
Health Technology Assessments, Rational Use of Drugs, Evidence-Based Medicine and Relative Effectiveness:Four Names for One Action
By Jacob Arfwedson, Centre for the New Europe and Peter J. Pitts, Center for Medicine in the Public Interest -
By Center for Medicine in the Public Interest
-
By Peter J. Pitts, Center for Medicine in the Public Interest
-
By Peter J. Pitts and Robert Goldberg, Center for Medicine in the Public Interest
-
By Peter J. Pitts, Center for Medicine in the Public Interest
-
By Peter J. Pitts and Robert Goldberg, Center for Medicine in the Public Interest
|
© 2010 The Stockholm Network